Parry-Romberg Syndrome and Localized Cranial Scleroderma Management

Epidemiology

The incidence of juvenile localized scleroderma is approximately 3.4 cases per million children per year, with a female to male ratio of 2.4:1 and a mean age of onset of 7.3 years 2

Localized Cranial Scleroderma presents with linear sclerotic plaques and active inflammatory lesions, which may appear as "en coup de sabre" and can involve the scalp leading to alopecia, with skin changes including hyperpigmentation and induration 3, 1

Comprehensive clinical evaluation is essential, with referral to specialized rheumatology centers for patients with suspected linear morphea or PRS, and skin biopsy is recommended when diagnostic uncertainty exists 3, 1
Standardized assessment tools such as the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) should be used to evaluate disease activity (LoSSI) and damage (LoSDI) 2, 1
MRI of the head is highly recommended for all patients with facial and head involvement at the time of diagnosis, regardless of neurological symptoms 2, 1

First-line systemic therapy for active, potentially disfiguring forms of both conditions is methotrexate (MTX) at 15 mg/m²/week combined with systemic corticosteroids during the initial inflammatory phase, with MTX maintained for at least 12 months after achieving clinical improvement before tapering 3, 1
Second-line therapy for MTX-refractory or MTX-intolerant patients is mycophenolate mofetil (500-1000 mg/m²) 3

Regular clinical assessment using LoSCAT is recommended to monitor disease activity and response to treatment, with monitoring for MTX side effects and ophthalmological follow-up considered for all patients, especially those with facial and scalp lesions 3, 1, 2